Table 1.

Multivariate analysis of DFS including clinical, pathologic, mutational, immunologic variables, and CMS combination (model 1).

Term	HR	95% CI	P
Age:
>70 y vs. ≤70 y	1.22	0.93–1.59	0.15
Gender:
Male vs. female	1.14	0.95–1.37	0.17
WHO score:
1–2 vs. 0	1.40	1.13–1.73	0.002
Bowel obstruction or perforation:
Yes vs. no	1.26	1.02–1.55	0.035
T stage:
T4 vs. T1–T3	2.05	1.69–2.49	<0.0001
N stage:
N2 vs. N1	1.92	1.6–2.3	<0.0001
Grade:
G1–G2 vs. G3–G4	1.14	0.91–1.41	0.25
RAS statusa
RAS mutated vs. RAS wildtype	1.40	1.17–1.68	0.0003
T-cell tumor infiltration:
Low and intermediate vs. high infiltration	1.42	1.16–1.74	0.0006
CMS combination:
High-risk vs. low-risk CMS combination	1.74	1.38–2.19	<0.0001

Note: R² = 0.118; likelihood ratio = 194.7; degree of freedom = 10; Harrell C-index = 0.685. Model 1 versus model 0 likelihood ratio test P < 0.0001 (χ² test); C-indexes are statistically significantly different (P < 0.03).

Abbreviations: WHO, World Health Organization; y, years.

^aKRAS or NRAS.